Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 9, 1997, Pages 1957-1960

  Krishnarao, Tangella V ^c   Galgiani, John N ^a,b,c,d  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; PNEUMOCANDIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECT; DRUG SCREENING; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL;

EID: 0030779919     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.9.1957     Document Type: Article

References (26)

1. Albertson, G. D., M. Niimi, R. D. Cannon, and H. F. Jenkinson. 1996. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Amimicrob. Agents Chemother. 40:2835-2841.
2. Calhoun, D. L., and J. N. Galgiani. 1984. Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media. Antimicrob. Agents Chemother. 26:364-367.
3. Cook, R. A., K. A. McIntyre, and J. N. Galgiani. 1990. Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilulion broth susceptibility test results for yeasts. Antimicrob. Agents Chemother. 34:1542-1545.
4. Debono, M., and R. S. Gordee. 1994. Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol. 48:471-497.
5. Dick, J., W. Merz, and R. Saral. 1980. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob. Agents Chemother. 18:158-163.
6. Dubé, M. P., P. N. R. Heseltine, M. G. Rinaldi, S. Evans, and B. Zawacki. 1994. Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clin. Infect. Dis. 18:77-82.
7. Ernst, M. E., M. E. Klepser, E. J. Wolfe, and M. A. Pfaller. 1996. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagn. Microbiol. Infect. Dis. 26:125-131.
8. Franzot, S. P., and A. Casadevall. 1997. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. 41:331-336.
9. Galgiani, J. N., and M. L. Lewis. 1997. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob. Agents Chcmother. 41:180-183.
10. Galgiani, J. N., and D. A. Stevens. 1976. Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob. Agents Chcmother. 10:721-726.
11. Galgiani, J. N., and D. A. Stevens. 1978. Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob. Agents Chemother. 13:249-254.
12. Heald, A. E., G. M. Cox, W. A. Schell, J. A. Bartlett, and J. R. Perfect. 1996. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS 10:263-268.
13. Kurtz, M. B., E. M. Bernard, F. F. Edwards, J. A. Marrinan, J. Dropinski, C. M. Douglas, and D. Armstrong. 1995. Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob. Agents Chemother. 39:1784-1789.
14. McIntyre, K. A., and J. N. Galgiani. 1989. pH and other effects on the antifungal activity of cilofungin (LY121019). Antimicrob. Agents Chemother. 33:731-735.
15. McIntyre, K. A., and J. N. Galgiani. 1989. In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob. Agents Chemother. 33:1095-1100.
16. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. Peng, T., and J. N. Galgiani. 1993. In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob. Agents Chemother. 37:2126-2131.
18. Pfaller, M. A., L. Burmeister, M. S. Bartlett, and M. G. Rinaldi. 1988. Multicenter evaluation of four methods of yeast inoculum preparation. J. Clin. Microhiol. 26:1437-1441.
19. Pfaller, M. A., I. Cabezudo, R. Hollis, B. Hudson, and R. P. Wenzel. 1990. The use of biotyping and DNA fingerprinting in typing Candida albicans from hospitalized patients. Diagn. Microbiol. Infect. Dis. 13:481-489.
20. Pfaller, M. A., S. A. Messer, and S. Coffman. 1997. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. 41:763-766.
21. Reagan, D. R., M. A. Pfaller, R. J. Hollis, and R. P. Wenzel. 1990. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J. Clin. Microbiol. 28:2733-2738.
22. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. Van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, M. J. Levenstein, and C. D. Webb. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
23. Rogers, T. E., and J. N. Galgiani. 1986. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob. Agents Chemother. 30:418-422.
24. Sterling, T. R., R. A. Gasser, Jr., and A. Ziegler. 1996. Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Clin. Infect. Dis. 23:187-188.
25. Villareal, K. M., R. A. Cook, J. N. Galgiani, R. P. Wenzel, P. G. Pappas, J. C. Pottage, Jr., H. A. Gallis, and L. R. Crane. 1994. Comparative analysis of three antifungal susceptibility test methods against prospectively collected Candida species. Diagn. Microbiol. Infect. Dis. 18:89-94.
26. Witt, M. D., R. J. Lewis, R. A. Larsen, E. N. Milefchik, M. A. E. Leal, R. H. Haubrich, J. A. Richie, J. E. Edwards, Jr., and M. A. Ghannoum. 1996. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin. Infect. Dis. 22:322-328.